Abaloparatide (Tymlos): Evidence, Mechanism, Dosing & Legal Status

Abaloparatide is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), given once daily by subcutaneous injection to build new bone in osteoporosis.4 Where most peptides discussed in recovery and longevity circles rest on animal data, abaloparatide sits at the opposite end of the evidence spectrum: a fully approved pharmaceutical with reproducible human fracture-reduction data. This monograph lays out what is proven, what is hyped, and where the genuine uncertainties remain.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Abaloparatide is a prescription-only, FDA-approved drug that must be prescribed, dosed and monitored by a licensed clinician. Dosing figures are reported strictly as documented in FDA labeling and the published literature. Consult a licensed clinician before any health decision.

What is abaloparatide and how does it work?

Abaloparatide is a 34-residue peptide analog of human PTHrP(1-34). It shares roughly 76% homology with PTHrP(1-34) and 41% with PTH(1-34) — teriparatide — and was engineered for peptide stability, potent bone-anabolic activity and low calcium-mobilizing potential.54 It is a selective agonist of the parathyroid hormone type 1 receptor (PTH1R), the common receptor for both PTH and PTHrP.1

The mechanistic distinction from teriparatide is conformational. PTH1R exists in two states: a high-affinity, long-lived R0 state and a transient, G-protein-coupled RG state. Abaloparatide preferentially binds the RG conformation, producing a more transient cAMP signal via Gs and adenylate cyclase, whereas teriparatide binds R0 more strongly and produces a more prolonged signal that drives greater osteoclast activation.4 This RG-selectivity is the mechanistic explanation for abaloparatide's anabolic window — robust osteoblast-driven bone formation with comparatively less bone resorption and less calcium mobilization.414 Once-daily, pulsatile administration stimulates new bone formation on trabecular and cortical surfaces,6 and in Phase 3 trials it raised the formation marker P1NP more than the resorption marker CTX, consistent with a net anabolic effect.4

The pharmacokinetics reinforce the design. Absolute bioavailability of the 80 µg subcutaneous dose is about 36%, time to peak roughly 0.5 hours, plasma protein binding about 70%, and the elimination half-life is approximately one hour, cleared by non-specific enzymatic proteolysis rather than CYP metabolism.4 That short half-life produces the brief, pulsatile receptor exposure that favors formation over resorption, and it is why the drug is injected daily rather than taken orally.4

What is the evidence by indication?

Abaloparatide is one of the few peptides in this encyclopedia with adequately powered, registered human RCTs. The pivotal data come from two Phase 3 trials, one in women and one in men, summarized below.

The ACTIVE trial (Abaloparatide Comparator Trial In Vertebral Endpoints) randomized 2,463 postmenopausal women with osteoporosis at 28 sites in 10 countries to abaloparatide 80 µg daily (n=824), placebo (n=821), or open-label teriparatide 20 µg daily (n=818) for 18 months.1 New morphometric vertebral fractures fell about 86% versus placebo, with significant reductions in nonvertebral, clinical and major osteoporotic fractures, and BMD gains at lumbar spine, total hip and femoral neck were all significantly greater than placebo (P < .001).1 Notably, hypercalcemia was lower with abaloparatide than teriparatide (3.4% vs 6.4%; P = .006), and the registry record can be reviewed on PubMed.2 ACTIVExtend then continued participants on open-label alendronate, showing benefits were maintained when the anabolic was followed by an antiresorptive,17 and a network meta-analysis corroborated the fracture efficacy.18 Subgroup analyses confirmed benefit across baseline fracture-risk strata and in younger postmenopausal women.1920

The ATOM trial (NCT03512262) randomized 228 men aged 40-85 (2:1) to abaloparatide or placebo for 12 months. At 12 months, BMD gains were significantly greater with abaloparatide: lumbar spine +8.48% vs +1.17%, total hip +2.14% vs +0.01%, and femoral neck +2.98% vs +0.15% (all P < .0001).3 A 3D-DXA sub-analysis showed gains in both trabecular and cortical compartments of the proximal femur.21 ATOM supported the December 2022 FDA approval in men — but it was powered for BMD, not fracture reduction, so fracture benefit in men is extrapolated rather than independently demonstrated.9

What doses appear in the literature?

Reported as documented in FDA labeling and trials — informational only, not a protocol. The labeled dose is 80 µg subcutaneously once daily, injected into the periumbilical abdomen with site rotation, supplied as a prefilled multi-dose pen.45 Because orthostatic hypotension can occur within about four hours, the first dose is given where the patient can sit or lie down.4 The original ACTIVE/labeling course was 18 months, and cumulative lifetime use of abaloparatide plus other PTH analogs should not exceed 2 years.41 Anabolic courses should be followed by an antiresorptive such as alendronate to preserve gains, with adequate calcium and vitamin D intake.174 An investigational transdermal microneedle patch (abaloparatide-sMTS) has been studied but did not replace the subcutaneous product as first-line.27

How safe is abaloparatide?

The most common adverse reactions in trials and labeling are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo and injection-site reactions; orthostatic hypotension can occur within about four hours of dosing.41 In the men's ATOM trial the most common events were injection-site reaction, dizziness, nasopharyngitis, arthralgia, bronchitis, hypertension and headache.3 Abaloparatide can cause hypercalcemia, hypercalciuria and kidney stones, though hypercalcemia was lower than with teriparatide in ACTIVE, so caution is warranted in patients with active urolithiasis or pre-existing hypercalcemia.14

The headline theoretical concern is osteosarcoma. In rats, abaloparatide caused a dose- and duration-dependent increase in osteosarcoma, prompting an original FDA boxed warning at the 2017 launch.12 After long-term post-marketing review across the PTH-analog class — large real-world observational data, the absence of a human osteosarcoma signal, the lifetime-exposure difference between rats and humans, and no bone tumors in monkeys — the FDA removed the boxed warning in 2021-2022.1023 Residual cautionary language remains, and the drug is avoided in anyone at increased baseline osteosarcoma risk: Paget disease of bone, unexplained elevated alkaline phosphatase, open epiphyses, bone metastases or prior skeletal radiation.47 There are no major CYP-mediated interactions, though caution applies with digoxin because hypercalcemia can predispose to digitalis toxicity; monitoring covers serum and urine calcium and orthostatic blood pressure.4

What is the FDA and WADA status in 2026?

Abaloparatide is a prescription-only, FDA-approved finished drug — emphatically not a research chemical. It was approved April 28, 2017 (Tymlos, NDA 208743) for postmenopausal women with osteoporosis at high fracture risk, and the indication was expanded to men on December 19, 2022.78 The original osteosarcoma boxed warning was removed in 2021-2022 following FDA review of long-term and real-world data.1011 Because an approved commercial product exists, abaloparatide is generally not a candidate for routine 503A pharmacy compounding — legitimate access is via the branded Tymlos product. It is not a DEA-controlled substance.22

For athletes the picture is nuanced rather than a flat ban. Abaloparatide is not explicitly named on the WADA Prohibited List, but as a peptide-hormone analog it could be scrutinized under the broad category S2 (peptide hormones, growth factors and mimetics).2426 There is no established performance-enhancing use; its niche is skeletal anabolism in osteoporosis. Any prescribed athlete should verify current status with their Anti-Doping Organization and obtain a Therapeutic Use Exemption if applicable.25

Bottom line. Abaloparatide is a genuinely high-evidence, FDA-approved osteoanabolic drug with a clear, reproducible signal: an 86% relative reduction in new vertebral fractures and significant nonvertebral-fracture reduction in women, plus large BMD gains in both sexes — Grade A.13 Its mechanistic distinction from teriparatide is real but its bone-formation superiority is partly hyped, long-term (>2 year) safety is deliberately uncharacterized hence the 2-year cap, and the rat osteosarcoma signal keeps the drug contraindicated in anyone with elevated baseline bone-tumor risk. For its on-label use — high-fracture-risk osteoporosis, a time-limited anabolic course followed by an antiresorptive — the evidence is solid and the verdict favorable; off-label or performance use has no supporting evidence. Regulatory facts here are current as of June 2026 and should be re-verified for label changes.